Trials / Completed
CompletedNCT02025556
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 297 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LBR-101 High Dose | Subcutaneously Administered High Dose LBR-101 Monthly x 3 |
| DRUG | LBR-101 Low Dose | Subcutaneously Administered Low Dose LBR-101 Monthly x 3 |
| DRUG | Placebo | Subcutaneously Administered Placebo (Vehicle) Monthly x 3 |
Timeline
- Start date
- 2014-01-31
- Primary completion
- 2015-01-31
- Completion
- 2015-03-31
- First posted
- 2014-01-01
- Last updated
- 2022-01-24
- Results posted
- 2022-01-24
Locations
63 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02025556. Inclusion in this directory is not an endorsement.